Linda Demer1, Yin Tintut. 1. Department of Medicine, University of California, Los Angeles, California 90095-1679, USA. Ldemer@mednet.ucla.edu
Abstract
PURPOSE: This review highlights the most recent publications addressing the relationship between bone and vascular calcification in patients with chronic and end-stage kidney disease. RECENT FINDINGS: The relatively new term 'chronic kidney disease-mineral bone disorder' reflects the growing reach of chronic kidney disease research into the realm of systems physiology, involving a triad of renal, skeletal, and vascular tissues. Recent studies address underlying mechanisms of the bone and vascular complications of chronic kidney disease and point to a variety of biochemical factors, including phosphatonins (fibroblast growth factor-23, matrix extracellular phosphoglycoprotein), bone morphogenetic protein 7, osteoprotegerin, matrix GLA protein, ectonucleotide pyrophosphatase/phosphodiesterase 1, alkaline phosphatase, and lipid oxidation products. Studies also demonstrate that agents used for treatment of one component of the triad often act on the other components of the triad - beneficially or adversely. These findings emphasize the importance of avoiding the subspecialty, single organ viewpoint when treating individual components of chronic kidney disease-mineral bone disorder. SUMMARY: The consistent synchrony among chronic kidney disease, aortic calcification, and bone loss offers clues to underlying mechanisms for the systemic abnormalities.
PURPOSE: This review highlights the most recent publications addressing the relationship between bone and vascular calcification in patients with chronic and end-stage kidney disease. RECENT FINDINGS: The relatively new term 'chronic kidney disease-mineral bone disorder' reflects the growing reach of chronic kidney disease research into the realm of systems physiology, involving a triad of renal, skeletal, and vascular tissues. Recent studies address underlying mechanisms of the bone and vascular complications of chronic kidney disease and point to a variety of biochemical factors, including phosphatonins (fibroblast growth factor-23, matrix extracellular phosphoglycoprotein), bone morphogenetic protein 7, osteoprotegerin, matrix GLA protein, ectonucleotide pyrophosphatase/phosphodiesterase 1, alkaline phosphatase, and lipid oxidation products. Studies also demonstrate that agents used for treatment of one component of the triad often act on the other components of the triad - beneficially or adversely. These findings emphasize the importance of avoiding the subspecialty, single organ viewpoint when treating individual components of chronic kidney disease-mineral bone disorder. SUMMARY: The consistent synchrony among chronic kidney disease, aortic calcification, and bone loss offers clues to underlying mechanisms for the systemic abnormalities.
Authors: H Sumino; S Ichikawa; S Kasama; T Takahashi; H Kumakura; Y Takayama; T Kanda; T Sakamaki; M Kurabayashi Journal: Maturitas Date: 2006-04-18 Impact factor: 4.342
Authors: Astrid Fahrleitner-Pammer; Johann Herberth; Steven R Browning; Barbara Obermayer-Pietsch; Gerhard Wirnsberger; Herwig Holzer; Harald Dobnig; Hartmut H Malluche Journal: J Bone Miner Res Date: 2008-11 Impact factor: 6.741
Authors: Daniela Veit Barreto; Fellype de Carvalho Barreto; Aluízio Barbosa de Carvalho; Lilian Cuppari; Sérgio Antonio Draibe; Maria Aparecida Dalboni; Rosa Maria Affonso Moyses; Kátia Rodrigues Neves; Vanda Jorgetti; Márcio Miname; Raul D Santos; Maria Eugênia F Canziani Journal: Am J Kidney Dis Date: 2008-09-27 Impact factor: 8.860
Authors: Sean Morony; Yin Tintut; Zina Zhang; Russell C Cattley; Gwyneth Van; Denise Dwyer; Marina Stolina; Paul J Kostenuik; Linda L Demer Journal: Circulation Date: 2008-01-02 Impact factor: 29.690
Authors: Rukshana C Shroff; Rosamund McNair; Nichola Figg; Jeremy N Skepper; Leon Schurgers; Ashmeet Gupta; Melanie Hiorns; Ann E Donald; John Deanfield; Lesley Rees; Catherine M Shanahan Journal: Circulation Date: 2008-10-06 Impact factor: 29.690
Authors: Paolo Raggi; Antonio Bellasi; Emiliana Ferramosca; Geoffrey A Block; Paul Muntner Journal: Hypertension Date: 2007-04-09 Impact factor: 10.190
Authors: Ken Iseri; Abdul Rashid Qureshi; Jonaz Ripsweden; Olof Heimbürger; Peter Barany; Ingrid B Bergström; Peter Stenvinkel; Torkel B Brismar; Bengt Lindholm Journal: J Bone Miner Metab Date: 2020-09-04 Impact factor: 2.626
Authors: David G Reid; Catherine M Shanahan; Melinda J Duer; Luis G Arroyo; Michael Schoppet; Roger A Brooks; Rachel C Murray Journal: J Lipid Res Date: 2012-05-31 Impact factor: 5.922